Sanofi India Limited (SANOFI) - Total Assets
Based on the latest financial reports, Sanofi India Limited (SANOFI) holds total assets worth Rs12.55 Billion INR (≈ $135.70 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sanofi India Limited - Total Assets Trend (2004–2025)
This chart illustrates how Sanofi India Limited's total assets have evolved over time, based on quarterly financial data. Also see how much is Sanofi India Limited worth for the company's overall valuation and market capitalisation.
Sanofi India Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
Sanofi India Limited's total assets of Rs12.55 Billion consist of 63.8% current assets and 36.2% non-current assets. Review SANOFI total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs2.30 Billion | 21.9% |
| Accounts Receivable | Rs1.78 Billion | 14.2% |
| Inventory | Rs3.12 Billion | 24.8% |
| Property, Plant & Equipment | Rs3.15 Billion | 25.1% |
| Intangible Assets | Rs7.00 Million | 0.1% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Sanofi India Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Sanofi India Limited share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sanofi India Limited's current assets represent 63.8% of total assets in 2025, a decrease from 72.0% in 2004.
- Cash Position: Cash and equivalents constituted 21.9% of total assets in 2025, down from 29.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2004.
- Asset Diversification: The largest asset category is property, plant & equipment at 25.1% of total assets.
Sanofi India Limited Competitors by Total Assets
Key competitors of Sanofi India Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
Sanofi India Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 1.57 | 2.67 |
| Quick Ratio | 1.00 | 0.87 | 2.13 |
| Cash Ratio | 0.47 | 0.34 | 0.00 |
| Working Capital | Rs3.09 Billion | Rs4.08 Billion | Rs11.46 Billion |
Sanofi India Limited - Advanced Valuation Insights
This section examines the relationship between Sanofi India Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.77 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -22.1% |
| Total Assets | Rs12.55 Billion |
| Market Capitalization | $768.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sanofi India Limited's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sanofi India Limited's assets decreased by 22.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sanofi India Limited (2004–2025)
The table below shows the annual total assets of Sanofi India Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Rs12.55 Billion ≈ $135.70 Million |
-22.15% |
| 2024-12-31 | Rs16.12 Billion ≈ $174.31 Million |
-6.01% |
| 2023-12-31 | Rs17.15 Billion ≈ $185.45 Million |
-17.23% |
| 2022-12-31 | Rs20.72 Billion ≈ $224.05 Million |
-32.32% |
| 2021-12-31 | Rs30.61 Billion ≈ $331.04 Million |
+4.88% |
| 2020-12-31 | Rs29.18 Billion ≈ $315.62 Million |
-10.05% |
| 2019-12-31 | Rs32.44 Billion ≈ $350.87 Million |
+8.73% |
| 2018-12-31 | Rs29.84 Billion ≈ $322.70 Million |
+7.45% |
| 2017-12-31 | Rs27.77 Billion ≈ $300.32 Million |
+9.33% |
| 2016-12-31 | Rs25.40 Billion ≈ $274.69 Million |
+5.63% |
| 2015-12-31 | Rs24.05 Billion ≈ $260.05 Million |
+7.95% |
| 2014-12-31 | Rs22.28 Billion ≈ $240.91 Million |
+20.75% |
| 2013-12-31 | Rs18.45 Billion ≈ $199.51 Million |
+13.09% |
| 2012-12-31 | Rs16.31 Billion ≈ $176.42 Million |
+8.57% |
| 2011-12-31 | Rs15.03 Billion ≈ $162.50 Million |
+6.68% |
| 2010-12-31 | Rs14.08 Billion ≈ $152.31 Million |
+16.85% |
| 2009-12-31 | Rs12.05 Billion ≈ $130.35 Million |
+13.14% |
| 2008-12-31 | Rs10.65 Billion ≈ $115.21 Million |
+16.36% |
| 2007-12-31 | Rs9.16 Billion ≈ $99.01 Million |
+6.68% |
| 2006-12-31 | Rs8.58 Billion ≈ $92.81 Million |
+23.53% |
| 2005-12-31 | Rs6.95 Billion ≈ $75.13 Million |
+21.59% |
| 2004-12-31 | Rs5.71 Billion ≈ $61.80 Million |
-- |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targoci… Read more